Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Retained Earnings (2016 - 2025)

vTv Therapeutics' Retained Earnings history spans 11 years, with the latest figure at -$326.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 9.0% year-over-year to -$326.7 million; the TTM value through Dec 2025 reached -$326.7 million, down 9.0%, while the annual FY2025 figure was -$326.7 million, 9.0% down from the prior year.
  • Retained Earnings for Q4 2025 was -$326.7 million at vTv Therapeutics, down from -$319.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$247.7 million in Q1 2022 and bottomed at -$326.7 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$280.9 million (2023), against an average of -$282.1 million.
  • The largest annual shift saw Retained Earnings rose 14.21% in 2021 before it decreased 10.86% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$248.8 million in 2021, then fell by 6.71% to -$265.5 million in 2022, then decreased by 5.84% to -$281.0 million in 2023, then fell by 6.65% to -$299.7 million in 2024, then dropped by 9.0% to -$326.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Retained Earnings are -$326.7 million (Q4 2025), -$319.6 million (Q3 2025), and -$310.9 million (Q2 2025).